BIG
CLBT icon

Brooklyn Investment Group’s Cellebrite CLBT Stock Holding History

Brooklyn Investment Group’s Portfolio CLBT Stock Details CLBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-25
Closed -$400 – 1057
2025
Q2 		$400 Buy
+25
New +$446 ﹤0.01% 3132

Other funds holding CLBT

TWCM
True Wind Capital Management San Francisco, California $226M AUM 2.79% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
VC
Voss Capital Houston, Texas $2.15B AUM 33.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
PP
Pertento Partners London, United Kingdom $1.86B AUM 53.86% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AE
Axon Enterprise Scottsdale, Arizona $19.1M AUM 8.75% 1-Year Est. Return
CCPM
Cooper Creek Partners Management New York $4.21B AUM 44.81% 1-Year Est. Return

Brooklyn Investment Group's CLBT Position: Q3 2025 in Review

Brooklyn Investment Group sold out of Cellebrite (CLBT) in Q3 2025, closing a stake of 25 shares — an estimated $400 sold.

Brooklyn Investment Group first reported a position in CLBT in Q2 2025 and held it in 1 quarter. The position peaked at $400 in Q2 2025. 197 funds tracked by Wall St. Rank hold CLBT as of Q3 2025.

  • Brooklyn Investment Group reported no remaining Cellebrite position as of Q3 2025 after selling out during the quarter.
  • Brooklyn Investment Group sold 25 Cellebrite shares in Q3 2025, an estimated $400.
  • Brooklyn Investment Group first reported a position in Cellebrite in Q2 2025 and held it in 1 quarter.
  • Brooklyn Investment Group's Cellebrite position peaked at $400 in Q2 2025.
  • 197 funds tracked by Wall St. Rank held Cellebrite as of Q3 2025.

Based on Brooklyn Investment Group's 13F filing for Q3 2025, filed 14 Nov 2025.